CLASSIFICATION
Glycoprotein Cytokine
ACNE
No
WATER RETENTION
No
HBR
No
HEPATOTOXICITY
No
AROMATIZATION
No
MANUFACTURER
Drogsan
WAREHOUSE
International Warehouse 2
SUBSTANCE
Erythropoietin
Indications for Dropoetin:
Dropoetin is specifically designed to manage anemia associated with chronic kidney failure in both adults and children undergoing hemodialysis or peritoneal dialysis. It is also effective for treating severe renal-derived anemia in adults with renal insufficiency who are not yet on dialysis. Additionally, Dropoetin helps adult cancer patients (with non-myeloid malignancies) undergoing chemotherapy by treating anemia and reducing the need for blood transfusions.
For HIV-infected adults receiving zidovudine treatment, Dropoetin is indicated to address anemia when endogenous Dropoetin levels are ?500 mU/ml. Patients with moderate anemia (hematocrit levels of 33-39%, hemoglobin levels of 10-13 g/dL, and no iron deficiency) scheduled for major elective surgeries may also benefit from Dropoetin to facilitate autologous blood collection and minimize the risk of allogeneic blood transfusions. This treatment is recommended only when blood conservation methods are insufficient for procedures expected to require significant blood volumes (4 or more units for females or 5 or more units for males).
Dropoetin is also utilized to stimulate erythropoiesis during the perioperative period, helping to decrease the likelihood of allogeneic blood transfusions and correct postoperative anemia in adults without iron deficiency undergoing major elective orthopedic surgeries. It is limited to patients with moderate anemia (e.g., Hb 10-13 g/dL) who lack access to autologous predonation programs and are anticipated to experience moderate blood loss (900 to 1800 ml). Finally, Dropoetin is indicated for treating anemia in patients with Low or Intermediate 1-risk Myelodysplastic Syndrome (MDS), specifically those with hemoglobin levels below 10 g/dL.
Using Dropoetin:
Administer Dropoetin precisely as directed by your healthcare provider. Always check the medication label for detailed dosing instructions. A Medication Guide will accompany your Dropoetin; be sure to read it thoroughly and refer back to it whenever you refill your prescription.
Dropoetin is typically administered via injection at a doctor's office, hospital, or clinic. If you plan to self-administer Dropoetin at home, a healthcare professional will provide guidance on its proper use. It is vital to follow these instructions closely and reach out to your healthcare provider if you have any questions.
When preparing your dose, adhere to the proper techniques to avoid contaminating the vial, syringe, or medication. Avoid touching the rubber stopper of the vial or the syringe needle with your fingers. Always double-check that you have drawn the correct dose before administration.
Do not shake Dropoetin, and ensure it hasn?t been shaken or frozen before use. Avoid diluting or mixing Dropoetin with other solutions unless specifically instructed by your physician. If you are using a single-dose vial, dispose of any unused medication once your dose has been taken. For questions regarding single-dose vials, consult your doctor, pharmacist, or healthcare provider.
Do not use Dropoetin if it appears cloudy, discolored, or contains particles, or if the vial is damaged or cracked. Store Dropoetin, along with syringes and needles, out of reach of children and pets. Never reuse needles, syringes, or other supplies. Consult your healthcare provider for proper disposal methods and follow all local regulations.
Continue taking Dropoetin even if you feel well and ensure you do not miss any doses. If a dose is missed, contact your doctor promptly. For any questions regarding Dropoetin, feel free to reach out to your healthcare provider.
Dropoetin Side Effects:
Be aware of the following serious adverse effects, which are discussed in more detail in other sections of the label:
- Increased Mortality
- Myocardial Infarction
- Stroke
- Thromboembolism
- Higher mortality risk and/or increased chance of tumor progression or recurrence in cancer patients
- Hypertension
- Seizures
- Pure Red Cell Aplasia (PRCA)
- Severe allergic reactions